Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Citrullination of glucokinase is linked to autoimmune diabetes.
Yang ML, Horstman S, Gee R, Guyer P, Lam TT, Kanyo J, Perdigoto AL, Speake C, Greenbaum CJ, Callebaut A, Overbergh L, Kibbey RG, Herold KC, James EA, Mamula MJ. Yang ML, et al. Among authors: greenbaum cj. Nat Commun. 2022 Apr 6;13(1):1870. doi: 10.1038/s41467-022-29512-0. Nat Commun. 2022. PMID: 35388005 Free PMC article.
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.
Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC. Seyfert-Margolis V, et al. Among authors: greenbaum cj. Diabetes. 2006 Sep;55(9):2588-94. doi: 10.2337/db05-1378. Diabetes. 2006. PMID: 16936208 Clinical Trial.
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.
Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group. Sosenko JM, et al. Among authors: greenbaum cj. Diabetes Care. 2007 Jan;30(1):38-42. doi: 10.2337/dc06-1615. Diabetes Care. 2007. PMID: 17192330
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group. Herold KC, et al. Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14. Clin Immunol. 2009. PMID: 19443276 Free PMC article. Clinical Trial.
Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1).
Sosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Cuthbertson D, Cowie C, Herold K, Eisenbarth G, Palmer JP; Diabetes Prevention Trial-Type 1 Study Group. Sosenko JM, et al. Among authors: greenbaum cj. Diabetes. 2010 Oct;59(10):2386-9. doi: 10.2337/db10-0534. Epub 2010 Aug 3. Diabetes. 2010. PMID: 20682683 Free PMC article.
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.
Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Herold KC, et al. J Immunol. 2011 Aug 15;187(4):1998-2005. doi: 10.4049/jimmunol.1100539. Epub 2011 Jul 20. J Immunol. 2011. PMID: 21775681 Free PMC article. Clinical Trial.
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Greenbaum CJ, et al. Diabetes. 2012 Aug;61(8):2066-73. doi: 10.2337/db11-1538. Epub 2012 Jun 11. Diabetes. 2012. PMID: 22688329 Free PMC article.
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Herold KC, et al. Among authors: greenbaum cj. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8. Diabetes. 2013. PMID: 23835333 Free PMC article. Clinical Trial.
246 results